pangi-shutterstock-com

PANGI / Shutterstock.com

6 June 2016Americas

Biosimilars and biologics: the life sciences battleground

“We’re looking back on a sustained attack on patents generally for the past decade,” explains Hans Sauer, deputy general counsel for intellectual property at the Biotechnology Innovation Organization (BIO).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Bayer gains exclusive licence for heart drug in Japan

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent

‘We took Ravgen head-on’: How we won zero-damages and others didn't